About Cellerant

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Cellerant's Press Releases

February 13, 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development

October 8, 2012
Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia

September 4, 2012
Cellerant Awarded $36.4 Million Option Under Existing U.S. Government Contract to Support Development of CLT-008 for Treatment of Acute Radiation Syndrome

June 15, 2012
Cellerant to Present at the International Society For Stem Cell Research (ISSCR) 10th Annual Meeting in Japan

more >

Copyright ©2006-2011 Cellerant Therapeutics, Inc.
Site design by Birdsall Interactive
Our Affiliates